Alembic Pharmaceuticals announced its Q2 FY26 results, reporting a 16% increase in revenue, reaching ₹1,910 Cr. EBITDA grew by 26% to ₹325 Cr, with a margin of 17%. Profit After Tax rose by 20% to ₹185 Cr. The company highlighted strong performance in India branded business and international generics.
Financial Performance Overview
Alembic Pharmaceuticals Ltd. has released its consolidated financial results for the second quarter and half-year ended September 30, 2025. Key highlights from the report include a significant increase in both revenue and profitability.
Key Financial Highlights for Q2 FY26
- Revenue from operations increased by 16% to ₹1,910 Cr.
- EBITDA increased by 26% to ₹325 Cr, representing a margin of 17%.
- Reported Profit After Tax stood at ₹185 Cr, up by 20%.
Segment Performance
The company witnessed growth across various segments:
- US Generics grew by 21%, reaching ₹566 Cr for the quarter.
- Ex-US International Generics saw a substantial increase of 31%, with revenue reaching ₹392 Cr.
- India Branded Business delivered a 5% YoY growth, reaching ₹639 Cr in revenue.
- API business grew by 15% to ₹261 Cr for the quarter.
Management Commentary
Mr. Shaunak Amin, MD of Alembic Pharmaceuticals, commented that the Q2 performance reflects continued momentum in core businesses and disciplined execution. The company has strengthened its presence across key markets while maintaining a sharp focus on profitability and operational excellence.
Strategic Focus and Investments
Alembic’s R&D investment remains a priority, accounting for around 10% of revenue, demonstrating a commitment to building a strong pipeline for future growth. The company is focused on complex, high-value areas like injectables, peptides, oral solids, and drug discovery. Recently, Alembic completed the acquisition of Utility Therapeutics.
Source: BSE